8-K
filed February 23, 2023, 6:59 PM ET
ticker PODD
CIK 0001145197
earnings
confidence high
sentiment positive
materiality 0.80
Insulet FY2022 revenue $1.3B (+19% YoY); Q4 revenue $369.7M (+20%); beats guidance; adjusted EPS $1.28
INSULET CORP
2022-FY EPS reported
$0.07
revenue$1,305,300,000
- Full year 2022 revenue $1.3B, up 18.8% (22.2% constant currency), exceeding guidance of 18-19% constant currency.
- Omnipod revenue $1.2B (+23.4%); U.S. Omnipod $884.8M (+35.8%); International $363.0M (+0.9% reported, +12.1% constant currency).
- GAAP net income $4.6M ($0.07 diluted EPS); adjusted net income $91.1M ($1.28 diluted EPS) excluding $57.9M MDC charge, $25.2M legal costs, $3.4M CEO transition costs.
- Gross margin 61.7% (down 670 bps); adjusted gross margin 66.2% excluding $57.9M charge for voluntary medical device correction notices for Omnipod DASH PDMs and Omnipod 5 Controllers.
- Q4 2022 revenue $369.7M (+20.1% reported, +22.6% constant currency); U.S. Omnipod revenue $276.2M (+45.0%).
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
INSULET CORP reported the full year ended December 31, 2022 results: revenue $1.3 billion, net income $4.6 million, EPS $0.07 per diluted share.
- Period
- the full year ended December 31, 2022
- Revenue
- $1.3 billion
- Net income
- $4.6 million
- EPS
- $0.07 per diluted share
- Result
- reported results
Exact text from the filing
Full year 2022 revenue of $1.3 billion, up 18.8%, or 22.2% in constant currency, compared to $1.1 billion in the prior year, exceeds the guidance range of 18% to 19% in constant currency ◦ Total Omnipod revenue of $1.2 billion, an increase of 23.4%, or 27.0% in constant currency ◦ U.S. Omnipod revenue of $884.8 million, an increase of 35.8% ◦ International Omnipod revenue of $363.0 million, an increase of 0.9%, or 12.1% in constant currency ◦ Drug Delivery revenue of $57.5 million, a decrease of 34.2% • Gross margin of 61.7%, down 670 basis points. Adjusted gross margin 1 of 66.2% excludes a charge of $57.9 million associated with the voluntary medical device correction (MDC) notices issued to replace Omnipod DASH ® Personal Diabetes Managers (PDMs) and Omnipod ® 5 Automated Insulin Delivery system (Omnipod 5) Controllers • Operating income of $37.6 million, or 2.9% of revenue, compared to $126.0 million, or 11.5% of revenue, in the prior year. Adjusted operating income 1 of $124.1 mil
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
INSULET CORP reported the fourth quarter ended December 31, 2022 results: revenue $369.7 million.
- Period
- the fourth quarter ended December 31, 2022
- Revenue
- $369.7 million
- Result
- reported results
Exact text from the filing
Fourth quarter 2022 revenue of $369.7 million, up 20.1%, or 22.6% in constant currency, compared to $307.7 million in the prior year, exceeds the guidance range of 11% to 14% in constant currency
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.